Compare Adaptive Biotechnologies Corp (ADPT) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Redwire Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $24.92 (market cap $4.04B), while Redwire Corporation trades at $13.51 (market cap $3.38B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| ADPT | RDW | |
|---|---|---|
Market Cap | $4.04B | $3.38B |
Sector | Health | Technology |
52-Week High | $25.45 | $25.90 |
52-Week Low | $12.30 | $5.06 |
Enterprise Value | $4.10B | $2.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Redwire (RDW) trades at $13.65, up 4.04% today, with strong technical momentum as moving averages signal bullish sentiment. The company reported record Q2 2026 revenue of $117.1 million and a growing $542.1 million backlog, though it continues to post significant net losses. Analyst consensus remains overwhelmingly positive with 80% buy ratings and a $17.50 price target, representing 28% upside potential from current levels.
While Redwire shows impressive revenue growth and defense contract momentum, investors face substantial risk from persistent losses, negative cash flow from operations, and high valuation multiples despite unprofitability. The company's pivot toward defense technology provides near-term stability but requires careful monitoring of margin improvement and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
